This company has been acquired
SURF Stock Overview
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Surface Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.07 |
| 52 Week High | US$1.43 |
| 52 Week Low | US$0.56 |
| Beta | 1.75 |
| 1 Month Change | 11.47% |
| 3 Month Change | 38.96% |
| 1 Year Change | -21.90% |
| 3 Year Change | -83.79% |
| 5 Year Change | -89.91% |
| Change since IPO | -91.97% |
Recent News & Updates
Recent updates
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically
Nov 07
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts
Aug 08Surface Oncology GAAP EPS of -$0.46 misses by $0.01
Aug 03Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
May 25News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts
May 11Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 23Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
Jan 18Is Surface Oncology (NASDAQ:SURF) A Risky Investment?
Nov 11Surface Oncology: Staying The Course
Oct 24Surface Oncology: A Diverse, But Early Pipeline
Jul 13Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?
Jun 07Surface Oncology EPS beats by $0.04, beats on revenue
May 05Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like
Mar 15Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 16
Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets
Dec 09What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?
Dec 08Surface Oncology shares rise 13% on Fast Track tag for SRF388
Nov 11Shareholder Returns
| SURF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.9% | -4.7% | -3.7% |
| 1Y | -21.9% | -2.7% | 20.2% |
Return vs Industry: SURF underperformed the US Biotechs industry which returned 3.5% over the past year.
Return vs Market: SURF underperformed the US Market which returned 7.4% over the past year.
Price Volatility
| SURF volatility | |
|---|---|
| SURF Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SURF's share price has been volatile over the past 3 months.
Volatility Over Time: SURF's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 35 | Rob Ross | www.surfaceoncology.com |
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No.
Surface Oncology, Inc. Fundamentals Summary
| SURF fundamental statistics | |
|---|---|
| Market cap | US$65.08m |
| Earnings (TTM) | -US$92.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs SURF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SURF income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$67.00m |
| Gross Profit | -US$67.00m |
| Other Expenses | US$25.50m |
| Earnings | -US$92.50m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SURF perform over the long term?
See historical performance and comparison